1.Sales and profit
See section β- Elanco had $4.7B of revenue in fiscal 2025, up 6.2% on the year before. Over five years, revenue changed +7.6% a year on average.
- Elanco lost $232M in fiscal 2025.
Elanco
ELAN NYSE Pharmaceuticals Financials FY2016βFY2025
Elanco had $4.7B of revenue in fiscal 2025, up 6.2% on the year before. Over five years, revenue changed +7.6% a year on average.
Download report
3-page PDF: the company, its results and charts with peers.
KIRAβs summary AI analyst
Hi! I read Elancoβs latest annual report (fiscal 2025). Here is what stands out:
2 strengths 3 to watch
2.Cash and shareholders
See section β- Free cash flow was $284M in fiscal 2025, 6.0% of revenue.
- Elanco returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count fell 0.2%.
- In the last 12 months, insiders bought $2.6M and sold $0.1M of shares on the open market.
3.Financial health
See section β- Elanco owes $3.5B more than it holds in cash, about 5.2 years of operating profit.
- Its return on capital was β0.1%: every 100 invested in the business earned about β0 in a year.
- Elanco passes 6 of 9 financial health tests (Piotroski F-score).
4.Price and value
See section β- At $22.52 a share, the company is worth $11.4B.
- Elanco grew sales faster than 2 of its 4 similar companies.
Elanco in 30 seconds
Good So-so Weak
Good
Are sales growing?
+6.2%
Yes. Sales grew 6.2% last year.
Weak
Does it make a profit?
β4.9%
No. It lost money last year.
So-so
Does profit turn into cash?
6.0%
Partly. 6.0% of sales ends up as free cash.
Weak
Is debt under control?
5.2x
Heavy. Repaying its debt would take 5.2 years of operating profit.
So-so
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$11.4B
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Results dates
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Elanco did it, and the next one. Share prices often move a lot on those days.
Next results
November 6, 2026
Friday Β· in 11 days
- Time
- Before the market opens
- Covers
- Period ended Sep 30, 2026
- Expected EPS
- $0.20
- Source
- Earnings calendar
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 5, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 6, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Feb 24, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 5, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 7, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 7, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Feb 25, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 7, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
Revenue and margins
KIRA Β· Elanco had $4.7B of revenue in fiscal 2025, up 6.2% on the year before. Over five years, revenue changed +7.6% a year on average.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY16
Revenue $2.9B
FY17
Revenue $2.9B
FY18
Revenue $3.1B
FY19
Revenue $3.1B
FY20
Revenue $3.3B
FY21
Revenue $4.8B
FY22
Revenue $4.4B
FY23
Revenue $4.4B
FY24
Revenue $4.4B
FY25
Revenue $4.7B
Revenue
Q3 '23
Revenue $1.1B
Q4 '23
Revenue $1.0B
Q1 '24
Revenue $1.2B
Q2 '24
Revenue $1.2B
Q3 '24
Revenue $1.0B
Q4 '24
Revenue $1.0B
Q1 '25
Revenue $1.2B
Q2 '25
Revenue $1.2B
Q3 '25
Revenue $1.1B
Q4 '25
Revenue $1.1B
Q1 '26
Revenue $1.4B
Q2 '26
Revenue $1.4B
Margins, % of revenue
FY16
Gross 51.6%
Operating β
Net β1.6%
FCF 1.6%
FY17
Gross 48.3%
Operating β
Net β10.8%
FCF 2.6%
FY18
Gross 48.7%
Operating β
Net 2.8%
FCF 11.5%
FY19
Gross 52.1%
Operating β
Net 2.2%
FCF 2.7%
FY20
Gross 49.1%
Operating β
Net β17.5%
FCF β5.4%
FY21
Gross 55.3%
Operating β
Net β10.1%
FCF 6.8%
FY22
Gross 56.6%
Operating β
Net β1.8%
FCF 6.4%
FY23
Gross 56.3%
Operating β
Net β27.9%
FCF 3.0%
FY24
Gross 54.9%
Operating β
Net 7.6%
FCF 8.9%
FY25
Gross 55.0%
Operating β
Net β4.9%
FCF 6.0%
Gross
Operating
Net
FCF
Margins, % of revenue
Q3 '23
Gross 54.4%
Operating β
Net β102.6%
FCF 15.5%
Q4 '23
Gross 50.1%
Operating β
Net β13.6%
FCF 11.2%
Q1 '24
Gross 57.3%
Operating β
Net 2.7%
FCF β1.8%
Q2 '24
Gross 58.2%
Operating β
Net β4.2%
FCF 14.0%
Q3 '24
Gross 52.2%
Operating β
Net 35.3%
FCF 11.7%
Q4 '24
Gross 50.9%
Operating β
Net β0.8%
FCF 12.8%
Q1 '25
Gross 57.3%
Operating β
Net 5.6%
FCF β5.8%
Q2 '25
Gross 57.5%
Operating β
Net 0.9%
FCF 14.5%
Q3 '25
Gross 53.4%
Operating β
Net β3.0%
FCF 11.2%
Q4 '25
Gross 51.5%
Operating β
Net β24.1%
FCF 4.0%
Q1 '26
Gross 57.3%
Operating β
Net 4.2%
FCF β2.8%
Q2 '26
Gross 58.3%
Operating β
Net 4.0%
FCF 17.8%
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Elanco lost $232M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY16
Net income β$47.9M
FY17
Net income β$311M
FY18
Net income $86.5M
FY19
Net income $68.0M
FY20
Net income β$574M
FY21
Net income β$483M
FY22
Net income β$78.0M
FY23
Net income β$1.2B
FY24
Net income $338M
FY25
Net income β$232M
Net income
Q3 '23
Net income β$1.1B
Q4 '23
Net income β$141M
Q1 '24
Net income $32.0M
Q2 '24
Net income β$50.0M
Q3 '24
Net income $364M
Q4 '24
Net income β$8.0M
Q1 '25
Net income $67.0M
Q2 '25
Net income $11.0M
Q3 '25
Net income β$34.0M
Q4 '25
Net income β$276M
Q1 '26
Net income $57.0M
Q2 '26
Net income $54.0M
Diluted EPS
FY16
Diluted EPS β$0.16
FY17
Diluted EPS β$1.06
FY18
Diluted EPS $0.28
FY19
Diluted EPS $0.18
FY20
Diluted EPS β$1.30
FY21
Diluted EPS β$0.99
FY22
Diluted EPS β$0.16
FY23
Diluted EPS β$2.50
FY24
Diluted EPS $0.68
FY25
Diluted EPS β$0.47
Diluted EPS
Q3 '23
Diluted EPS β$2.22
Q4 '23
Diluted EPS β$0.29
Q1 '24
Diluted EPS $0.06
Q2 '24
Diluted EPS β$0.10
Q3 '24
Diluted EPS $0.73
Q4 '24
Diluted EPS β$0.02
Q1 '25
Diluted EPS $0.13
Q2 '25
Diluted EPS $0.02
Q3 '25
Diluted EPS β$0.07
Q4 '25
Diluted EPS β$0.56
Q1 '26
Diluted EPS $0.11
Q2 '26
Diluted EPS $0.11
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was $284M in fiscal 2025, 6.0% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY16
Free cash flow $45.6M
FY17
Free cash flow $75.2M
FY18
Free cash flow $353M
FY19
Free cash flow $84.0M
FY20
Free cash flow β$176M
FY21
Free cash flow $324M
FY22
Free cash flow $281M
FY23
Free cash flow $131M
FY24
Free cash flow $394M
FY25
Free cash flow $284M
Free cash flow
Q3 '23
Free cash flow $165M
Q4 '23
Free cash flow $116M
Q1 '24
Free cash flow β$22.0M
Q2 '24
Free cash flow $166M
Q3 '24
Free cash flow $120M
Q4 '24
Free cash flow $130M
Q1 '25
Free cash flow β$69.0M
Q2 '25
Free cash flow $180M
Q3 '25
Free cash flow $127M
Q4 '25
Free cash flow $46.0M
Q1 '26
Free cash flow β$38.0M
Q2 '26
Free cash flow $244M
Cash from operations vs capital spending
FY16
Cash from operations $156M
Capital spending $110M
FY17
Cash from operations $174M
Capital spending $98.6M
FY18
Cash from operations $487M
Capital spending $135M
FY19
Cash from operations $224M
Capital spending $140M
FY20
Cash from operations β$41.0M
Capital spending $135M
FY21
Cash from operations $483M
Capital spending $159M
FY22
Cash from operations $452M
Capital spending $171M
FY23
Cash from operations $271M
Capital spending $140M
FY24
Cash from operations $541M
Capital spending $147M
FY25
Cash from operations $560M
Capital spending $276M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '23
Cash from operations $198M
Capital spending $33.0M
Q4 '23
Cash from operations $157M
Capital spending $41.0M
Q1 '24
Cash from operations $2.0M
Capital spending $24.0M
Q2 '24
Cash from operations $200M
Capital spending $34.0M
Q3 '24
Cash from operations $162M
Capital spending $42.0M
Q4 '24
Cash from operations $177M
Capital spending $47.0M
Q1 '25
Cash from operations β$4.0M
Capital spending $65.0M
Q2 '25
Cash from operations $237M
Capital spending $57.0M
Q3 '25
Cash from operations $219M
Capital spending $92.0M
Q4 '25
Cash from operations $108M
Capital spending $62.0M
Q1 '26
Cash from operations $13.0M
Capital spending $51.0M
Q2 '26
Cash from operations $277M
Capital spending $33.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
KIRA Β· Elanco returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count fell 0.2%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY16
Dividends $0.0M
Buybacks $0.0M
FY17
Dividends $0.0M
Buybacks $0.0M
FY18
Dividends $0.0M
Buybacks $0.0M
FY19
Dividends $0.0M
Buybacks $0.0M
FY20
Dividends $0.0M
Buybacks $0.0M
FY21
Dividends $0.0M
Buybacks $0.0M
FY22
Dividends $0.0M
Buybacks $0.0M
FY23
Dividends $0.0M
Buybacks $0.0M
FY24
Dividends $0.0M
Buybacks $0.0M
FY25
Dividends $0.0M
Buybacks $0.0M
Dividends
Buybacks
Dividends and buybacks
Q3 '23
Dividends $0.0M
Buybacks $0.0M
Q4 '23
Dividends $0.0M
Buybacks $0.0M
Q1 '24
Dividends $0.0M
Buybacks $0.0M
Q2 '24
Dividends $0.0M
Buybacks $0.0M
Q3 '24
Dividends $0.0M
Buybacks $0.0M
Q4 '24
Dividends $0.0M
Buybacks $0.0M
Q1 '25
Dividends $0.0M
Buybacks $0.0M
Q2 '25
Dividends $0.0M
Buybacks $0.0M
Q3 '25
Dividends $0.0M
Buybacks $0.0M
Q4 '25
Dividends $0.0M
Buybacks $0.0M
Q1 '26
Dividends $0.0M
Buybacks $0.0M
Q2 '26
Dividends $0.0M
Buybacks $0.0M
Dividends
Buybacks
Diluted shares outstanding (annual)
FY16
Diluted shares 0.29B
FY17
Diluted shares 0.29B
FY18
Diluted shares 0.31B
FY19
Diluted shares 0.37B
FY20
Diluted shares 0.44B
FY21
Diluted shares 0.49B
FY22
Diluted shares 0.49B
FY23
Diluted shares 0.49B
FY24
Diluted shares 0.50B
FY25
Diluted shares 0.50B
Insider trades
KIRA Β· In the last 12 months, insiders bought $2.6M and sold $0.1M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$2.6M
7 insiders
Sold, 12 months
$0.1M
1 insider
Of sales under plans
100%
$0.1M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Timothy J BettingtonSee Remarks | Sold plan | 4,350 | $23.00 | $0.1M | Form 4 |
| Aug 20, 2026 | Lawrence Erik KurziusDirector | Bought | 40,000 | $23.40 | $0.9M | Form 4 |
| Aug 18, 2026 | Shiv O'NeillGC and Corp Sec | Bought | 3,998 | $23.58 | $0.1M | Form 4 |
| Aug 12, 2026 | Michael J HarringtonDirector | Bought | 5,000 | $21.82 | $0.1M | Form 4 |
| Aug 7, 2026 | Paul HerendeenDirector | Bought | 10,000 | $23.69 | $0.2M | Form 4 |
| Aug 7, 2026 | Robert M VanHimbergenEVP and CFO | Bought | 4,200 | $23.08 | $0.1M | Form 4 |
| May 15, 2026 | Jeffrey N SimmonsPresident, CEO and Director, Director | Bought | 4,971 | $20.09 | $0.1M | Form 4 |
| May 15, 2026 | Rajeev A. ModiSee Remarks | Bought | 4,911 | $20.35 | $0.1M | Form 4 |
| Dec 12, 2025 | Lawrence Erik KurziusDirector | Bought | 10,000 | $21.30 | $0.2M | Form 4 |
| Dec 11, 2025 | Jeffrey N SimmonsPresident, CEO and Director, Director | Bought | 22,000 | $21.75 | $0.5M | Form 4 |
| Dec 11, 2025 | Rajeev A. ModiSee Remarks | Bought | 4,500 | $21.33 | $0.1M | Form 4 |
| Dec 11, 2025 | Robert M VanHimbergenEVP and CFO | Bought | 6,950 | $21.64 | $0.2M | Form 4 |
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
KIRA Β· Elanco owes $3.5B more than it holds in cash, about 5.2 years of operating profit.
Cash, debt and the ratios that show how comfortably Elanco can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY16
Cash $259M
Debt β
FY17
Cash $323M
Debt $0.0M
FY18
Cash $475M
Debt $2.5B
FY19
Cash $334M
Debt $2.4B
FY20
Cash $495M
Debt $6.1B
FY21
Cash $638M
Debt $6.3B
FY22
Cash $345M
Debt $5.8B
FY23
Cash $352M
Debt $5.8B
FY24
Cash $468M
Debt $4.3B
FY25
Cash $545M
Debt $4.0B
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $638M | $345M | $352M | $468M | $545M |
| Debt incl. finance leases | $6.3B | $5.8B | $5.8B | $4.3B | $4.0B |
| Net debt / EBITDA | 14.9x | 6.5x | β | 2.7x | 5.2x |
| Debt / equity | 0.8x | 0.8x | 0.9x | 0.7x | 0.6x |
| Interest coverage | β1.4x | 0.7x | β3.3x | 2.7x | β0.1x |
| Current ratio | 2.0x | 1.9x | 2.8x | 2.4x | 2.2x |
| Quick ratio | 1.2x | 1.0x | 1.4x | 1.3x | 1.1x |
| Total assets | $16.5B | $15.5B | $14.4B | $12.6B | $13.4B |
| Total liabilities | $9.0B | $8.2B | $8.1B | $6.5B | $6.8B |
| Shareholders' equity | $7.5B | $7.3B | $6.2B | $6.1B | $6.5B |
| Net debt (β = net cash) | $5.7B | $5.5B | $5.4B | $3.9B | $3.5B |
Returns on capital
KIRA Β· Its return on capital was β0.1%: every 100 invested in the business earned about β0 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY16
Return on capital β
Return on equity β
Return on assets β
FY17
Return on capital β
Return on equity β
Return on assets β
FY18
Return on capital 1.5%
Return on equity 1.3%
Return on assets 1.0%
FY19
Return on capital 1.9%
Return on equity 1.3%
Return on assets 0.8%
FY20
Return on capital β3.9%
Return on equity β8.2%
Return on assets β4.3%
FY21
Return on capital β1.9%
Return on equity β6.1%
Return on assets β2.8%
FY22
Return on capital 1.0%
Return on equity β1.1%
Return on assets β0.5%
FY23
Return on capital β5.9%
Return on equity β18.2%
Return on assets β8.3%
FY24
Return on capital 5.0%
Return on equity 5.5%
Return on assets 2.5%
FY25
Return on capital β0.1%
Return on equity β3.7%
Return on assets β1.8%
Return on capital
Return on equity
Return on assets
Piotroski F-score
KIRA Β· Elanco passes 6 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 4 / 9 | 6 / 9 | 6 / 9 |
| Accruals ratio | β10.1% | β1.5% | β6.1% |
| Altman Z'' | 0.84 | 1.88 | 1.38 |
Price and value
What does the share cost, and how does it compare?
Value Elanco yourself
KIRA Β· At $22.52 a share, the company is worth $11.4B.
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.
Discounted cash flow
Value per share
β
Adds net cash of β$3.5B and divides by 496.4M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Similar companies
KIRA Β· Elanco grew sales faster than 2 of its 4 similar companies.
Each companyβs latest fiscal year. Fiscal years end in different months, so periods donβt line up exactly.
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Elanco ELAN | $11.4B | 6.2% | β | 6.0% | β0.1% | β | 6 | |
| Jazz Pharmaceuticals JAZZ | $14.9B | 4.9% | β10.1% | 30.4% | β4.2% | 14.6x | 4 | Compare β |
| Amneal Pharmaceuticals AMRX | $6.7B | 8.1% | 13.1% | 8.9% | 16.1% | 41.6x | 7 | Compare β |
| Zoetis ZTS | $33.8B | 2.3% | β | 24.1% | 29.3% | 13.3x | 8 | Compare β |
| Bausch Health Companies BHC | $2.4B | 6.7% | 17.7% | 9.8% | 4.5% | β | 7 | Compare β |
All figures
Every number, year by year.
10 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $2.9B | $2.9B | $3.1B | $3.1B | $3.3B | $4.8B | $4.4B | $4.4B | $4.4B | $4.7B |
| Gross profit | $1.5B | $1.4B | $1.5B | $1.6B | $1.6B | $2.6B | $2.5B | $2.5B | $2.4B | $2.6B |
| Research and development | $266M | $252M | $247M | $270M | $329M | $369M | $321M | $327M | $344M | $368M |
| Interest expense | $0.0M | $0.0M | $29.6M | $79.0M | $150M | $236M | $241M | $277M | $296M | $206M |
| Pretax income | β$22.4M | β$233M | $114M | $78.0M | β$677M | β$571M | β$72.0M | β$1.2B | $488M | β$224M |
| Income tax | $25.5M | $78.1M | $27.6M | $10.0M | β$103M | β$88.0M | $6.0M | $36.0M | $150M | $8.0M |
| Net income | β$47.9M | β$311M | $86.5M | $68.0M | β$574M | β$483M | β$78.0M | β$1.2B | $338M | β$232M |
| Diluted EPS | β$0.16 | β$1.06 | $0.28 | $0.18 | β$1.30 | β$0.99 | β$0.16 | β$2.50 | $0.68 | β$0.47 |
| Diluted shares | 0.29B | 0.29B | 0.31B | 0.37B | 0.44B | 0.49B | 0.49B | 0.49B | 0.50B | 0.50B |
| Cash flow | ||||||||||
| Cash from operations | $156M | $174M | $487M | $224M | β$41.0M | $483M | $452M | $271M | $541M | $560M |
| Capital expenditure | $110M | $98.6M | $135M | $140M | $135M | $159M | $171M | $140M | $147M | $276M |
| Free cash flow | $45.6M | $75.2M | $353M | $84.0M | β$176M | $324M | $281M | $131M | $394M | $284M |
| Depreciation and amortization | $254M | $318M | $296M | $314M | $517M | $716M | $682M | $694M | $662M | $680M |
| Stock-based compensation | $20.4M | $25.0M | $26.0M | $49.0M | $47.0M | $66.0M | $59.0M | $46.0M | $55.0M | $68.0M |
| Acquisitions | $45.0M | $882M | $0.0M | $33.0M | $5.0B | $342M | $0.0M | $19.0M | $41.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $259M | $323M | $475M | $334M | $495M | $638M | $345M | $352M | $468M | $545M |
| Total debt | β | $0.0M | $2.5B | $2.4B | $6.1B | $6.3B | $5.8B | $5.8B | $4.3B | $3.8B |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $255M |
| Current assets | β | $2.1B | $2.5B | $2.4B | $3.4B | $3.3B | $3.3B | $3.4B | $3.2B | $3.5B |
| Current liabilities | β | $643M | $971M | $819M | $2.1B | $1.6B | $1.7B | $1.2B | $1.3B | $1.6B |
| Inventory | $0.0M | $1.1B | $1.0B | $1.1B | $1.6B | $1.4B | $1.5B | $1.7B | $1.6B | $1.7B |
| Property and equipment, net | β | $920M | $922M | $955M | $1.3B | $1.1B | $999M | $1.0B | $993M | $1.4B |
| Total assets | β | $8.9B | $9.0B | $9.0B | $17.7B | $16.5B | $15.5B | $14.4B | $12.6B | $13.4B |
| Total liabilities | β | $1.2B | $3.8B | $3.4B | $9.2B | $9.0B | $8.2B | $8.1B | $6.5B | $6.8B |
| Shareholders' equity | $7.0B | $7.8B | $5.2B | $5.5B | $8.5B | $7.5B | $7.3B | $6.2B | $6.1B | $6.5B |
| Margins | ||||||||||
| Gross margin | 51.6% | 48.3% | 48.7% | 52.1% | 49.1% | 55.3% | 56.6% | 56.3% | 54.9% | 55.0% |
| EBITDA margin | 8.0% | 3.0% | 14.3% | 15.3% | β0.3% | 8.0% | 19.3% | β5.1% | 32.6% | 14.0% |
| Net margin | β1.6% | β10.8% | 2.8% | 2.2% | β17.5% | β10.1% | β1.8% | β27.9% | 7.6% | β4.9% |
| FCF margin | 1.6% | 2.6% | 11.5% | 2.7% | β5.4% | 6.8% | 6.4% | 3.0% | 8.9% | 6.0% |
| Returns | ||||||||||
| Return on capital | β | β | 1.5% | 1.9% | β3.9% | β1.9% | 1.0% | β5.9% | 5.0% | β0.1% |
| Return on capital employed | β | β | 1.8% | 1.9% | β4.4% | β2.2% | 1.2% | β6.8% | 6.4% | β0.2% |
| Return on equity | β | β | 1.3% | 1.3% | β8.2% | β6.1% | β1.1% | β18.2% | 5.5% | β3.7% |
| Return on assets | β | β | 1.0% | 0.8% | β4.3% | β2.8% | β0.5% | β8.3% | 2.5% | β1.8% |
| Growth | ||||||||||
| Revenue growth | β | β0.8% | 6.2% | 0.1% | 6.6% | 45.6% | β7.4% | 0.1% | 0.5% | 6.2% |
| Net income growth | β | β | β | β21.4% | β944.1% | β | β | β | β | β168.6% |
| EPS growth | β | β | β | β35.7% | β822.2% | β | β | β | β | β169.1% |
| FCF growth | β | 64.9% | 369.2% | β76.2% | β309.5% | β | β13.3% | β53.4% | 200.8% | β27.9% |
| Share count change | β | 0.0% | 7.0% | 18.0% | 19.2% | 10.4% | 0.2% | 0.8% | 1.0% | β0.2% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β3.8x | 4.5x | 4.3x | β | 14.9x | 6.5x | β | 2.7x | 5.2x |
| Debt / equity | β | 0.0x | 0.5x | 0.4x | 0.7x | 0.8x | 0.8x | 0.9x | 0.7x | 0.6x |
| Interest coverage | β | β | 4.9x | 2.0x | β3.5x | β1.4x | 0.7x | β3.3x | 2.7x | β0.1x |
| Current ratio | β | 3.3x | 2.6x | 2.9x | 1.7x | 2.0x | 1.9x | 2.8x | 2.4x | 2.2x |
| Quick ratio | β | 1.7x | 1.6x | 1.6x | 0.9x | 1.2x | 1.0x | 1.4x | 1.3x | 1.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.8% | 3.4% | 4.4% | 4.6% | 4.1% | 3.3% | 3.9% | 3.2% | 3.3% | 5.9% |
| Stock comp / revenue | 0.7% | 0.9% | 0.9% | 1.6% | 1.4% | 1.4% | 1.3% | 1.0% | 1.2% | 1.4% |
| Payouts / FCF | 0.0% | 0.0% | 0.0% | 0.0% | β | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | β | 6.0 | 2.0 | 6.0 | 5.0 | 4.0 | 6.0 | 6.0 |
| Altman Z'' | β | 8.0 | 2.7 | 3.0 | 1.2 | 1.2 | 1.5 | 0.8 | 1.9 | 1.4 |
| Accruals ratio | β | β | β4.5% | β1.7% | β4.0% | β5.7% | β3.3% | β10.1% | β1.5% | β6.1% |
Source: SEC EDGAR XBRL filings (CIK 0001739104). Data updated October 14, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.